Best Genomics Companies in Michigan, United States

Precision oncology company enabling smarter cancer treatment through advanced biomarker algorithms. The company focuses on next-generation precision oncology, developing predictive diagnostic tools for cancer treatment. They offer innovative solutions like Antibody-drug Conjugate Treatment Response Scores and Immunotherapy Response Score, utilizing proprietary calculation methods and algorithms. These tools aim to predict patient response to therapies, ensuring individuals receive the most effective treatment. The company's approach combines tumor biology and microenvironment analysis, incorporating factors like tumor mutation burden and protein expression. They strive to accelerate the impact of precision medicine, offering advanced algorithmic biomarkers for antibody drug conjugates and immunotherapy. The company is committed to improving cancer care through scientific innovation and data-driven decision-making. This is a B2B, SaaS, and tech company in the healthcare sector.

Funding rounds

• Nov 2024Series C$6.1M
• Jul 2021Series C$90M
• Nov 2020Series B$5M
• May 2018Series B$26M

Founders & team

Scott TomlinsCo-FounderDan RhodesCo-Founder & CEO

Investors

Arboretum Ventures, Baird Capital, eLab Ventures, Wellington, Monashee Investment Management, HIGHSIDE Global

Provider of software, data, and services for genomic information analysis. The company offers platforms for germline and somatic variant interpretation. It facilitates access to article information on variants and curated germline variant content. The cancer knowledgebase interprets cancer variants, connecting them to therapies and clinical trials.

Provider of bioinformatics software tools focused on multi-omics pathway analysis. The company offers iPathwayGuide, is a next-generation pathway analysis platform that enables rapid and accurate interpretation of gene expression and other omics data.

Developer of hybrid corn varieties using ancestral strains for resilience. These varieties are developed to withstand drought, temperature extremes, diseases, insects, and weeds. The hybrids offer an alternative to genetically modified varieties that require herbicides, insecticides, and fungicides. Commercial production and marketing is underway with seed company partners.

Immunis provides a patented platform for the detection of cancer. The intelligentia platform combines machine learning for the development of disease-specific algorithms. The immune system rapidly reacts to threats, triggering an internal amplification structure that causes changes to RNA expression levels within immune cells. It provides real-time surveillance of gene expression of monocytes and lymphocytes obtained from a patient enables the detection of immune-response signal changes.

Funding rounds

• Sep 2021Series C—
• Sep 2019Series B$22.2M

Founders & team

Christopher ThibodeauPresident & CEO

Investors

Savitr Capital

Provider of liquid biopsy technology to monitor circulating tumor cells (CTC). The company offers an instrument system and reagent kit that allows for the separation, detection, and retrieval of CTCs from peripheral whole blood as an alternative to traditionally painful and invasive biopsies. The company's product will allow researchers to identify, capture rare and difficult to harvest cancer cells in a microfluidic chip and also enable them to conduct a downstream molecular analysis.

Developer of liquid biopsy tools. The company manufactures tools for developing rapid, low-cost solutions for the assessment of biomolecules via liquid biopsy.

Funding rounds

• May 2022Series A$18.7M

Founders & team

Matthew CooperCEO

Investors

Arboretum Ventures

NeuMoDx is developing a patent-pending platform for low-cost molecular testing. It integrates magnetic particle affinity capture and real-time Polymerase Chain Reaction (PCR) chemistry in a multi-sample microfluidic cartridge. Its lead product NeuMoDx 500 is a molecular IVD system that is a fully automated, random access platform capable of performing RNA and DNA-based assays.

Swift Biosciences is developing new methods and technologies for sample and library prep for next generation sequencing. It offers Accel-NGS DNA library kits ( Illumina NGS & Ion-Torrent platforms) which are designed to accelerate sample preparation for DNA sequencing and deliver more usable data from NGS instruments; Accel-Amplicon Panels for detecting and screening clinically relevant mutations. It also offers myT Primers used in quantitative polymerase chain reaction (qPCR) detection of key cancer mutations.

Provider of reagents and kits for pre-analytical amplification technologies. The company has three reagent kits to use with Illumina NGS systems and two kits to use with microarray and PCR systems.

PCR assay design software and services for life-changing organizations. They provide multiplex PCR primer design software, qPCR kits, and assay design services. Their software offerings include tools for panel design, consensus panel design, simulation, copy number determination, and genome scanning. They serve markets like academics, agriculture, biotechnology, pharmaceuticals, and government agencies. They offer solutions for organizations facing polymerase chain reaction challenges, helping them fight viruses, cancer, and illness. Their services include consulting and custom assay design. They aim to accelerate research and development, saving time and resources for their clients. They offer software demos and customer support programs. Their products are used for applications like cancer panels, antimicrobial resistance, and infectious disease sub-population differentiation. They provide tools for optimizing assay specificity and sensitivity, and eliminating false positives. They are a B2B tech company offering software and services.

Informatics solutions for cancer research, variant prioritization, and reporting. The company provides software and services to manage and interpret variant data from next-generation sequencing (NGS) and cytogenetics workflows. It helps researchers prioritize variants, identify cancer drivers, and create custom reports integrating NGS and cytogenetics data. The workflow enables high-quality data analysis, annotates driver variants, and links biomarkers to a curated knowledgebase of relevant evidence. Key offerings include Torrent Suite Software, Ion Reporter Software, and Oncomine Reporter, providing intuitive interfaces and streamlined bioinformatics paths to discovery. The company supports cancer research by offering tools for sequence analysis, variant annotation, and report generation, facilitating a deeper understanding of cancer genomics and transcriptomics. This is a B2B, SaaS, and Software business model.